OCUL

8.50

0.59% 0.05

Dopo l'orario di chiusura: 8.63 0.13 +1.53%

Ocular Therapeutix Inc (OCUL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché OCUL Giù? Forum Previsione

Precedente Chiudi:

$8.45

Aprire:

$8.31

Volume 24 ore:

1.29M

Relative Volume:

1.15

Capitalizzazione di mercato:

$1.34B

Reddito:

$61.10M

Utile/perdita netta:

$-138.36M

Rapporto P/E:

-7.0833

EPS:

-1.2

Flusso di cassa netto:

$-90.59M

1 W Prestazione:

-2.19%

1M Prestazione:

-3.19%

6M Prestazione:

+39.80%

1 anno Prestazione:

+116.84%

Intervallo 1D:

$8.31

$8.62

Intervallo di 1 settimana:

$8.15

$9.21

Portata 52W:

$3.7599

$11.78

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Nome

Ocular Therapeutix Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

781-357-4000

Indirizzo

15 CROSBY DRIVE, BEDFORD, MA

Dipendente

267

Cinguettio

@OCUTX

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

OCUL's Discussions on Twitter

Confronta OCUL con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OCUL Ocular Therapeutix Inc	8.50	1.34B	61.10M	-138.36M	-90.59M	-1.35
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-06-20	Aggiornamento	TD Cowen	Hold → Buy
2024-05-31	Ripresa	Piper Sandler	Overweight
2024-02-09	Iniziato	BofA Securities	Buy
2023-04-21	Iniziato	Robert W. Baird	Outperform
2022-08-10	Ripresa	Berenberg	Buy
2021-08-10	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-12-28	Downgrade	H.C. Wainwright	Buy → Neutral
2020-12-17	Iniziato	Berenberg	Buy
2020-11-13	Reiterato	Raymond James	Strong Buy
2020-08-10	Reiterato	H.C. Wainwright	Buy
2020-03-03	Aggiornamento	Raymond James	Outperform → Strong Buy
2019-05-21	Downgrade	Cowen	Outperform → Market Perform
2019-05-21	Reiterato	H.C. Wainwright	Buy
2019-05-21	Downgrade	Raymond James	Strong Buy → Outperform
2018-12-03	Reiterato	Cantor Fitzgerald	Overweight
2018-11-15	Iniziato	Raymond James	Strong Buy
2018-09-07	Iniziato	Piper Jaffray	Overweight
2017-10-24	Iniziato	Guggenheim	Buy
2017-07-26	Iniziato	H.C. Wainwright	Buy
2017-07-12	Reiterato	Cantor Fitzgerald	Overweight
2017-06-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2017-02-10	Iniziato	Cantor Fitzgerald	Overweight
2016-11-15	Reiterato	RBC Capital Mkts	Outperform
2016-08-11	Iniziato	JMP Securities	Mkt Outperform
2016-02-17	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2015-10-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2015-08-13	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie

Dec 19, 2024

Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week - Yahoo Finance

Dec 19, 2024

How to Take Advantage of moves in (OCUL) - Stock Traders Daily

Dec 19, 2024

Dec 18, 2024

Wellington Management Group LLP Purchases 148,310 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Dec 18, 2024

Dec 17, 2024

Last Week's Biggest Stock Movers: Mylan, Ocular Therapeutix - AOL

Dec 17, 2024

Dec 15, 2024

Ocular Therapeutix Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St

Dec 15, 2024

Dec 14, 2024

Fmr LLC Purchases 428,335 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Dec 14, 2024

Dec 13, 2024

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 13, 2024

Ocular Therapeutix Grants Major Stock Awards Package to New Executive, Including 285K Shares - StockTitan

Dec 13, 2024

Dec 12, 2024

Verition Fund Management LLC Purchases Shares of 62,501 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Dec 12, 2024

Dec 10, 2024

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Dec 10, 2024

Ocular Therapeutix CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Dec 10, 2024

Charles Schwab Investment Management Inc. Has $9.66 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Dec 10, 2024

Dec 07, 2024

Point72 Asset Management L.P. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Dec 07, 2024

Dec 05, 2024

492,900 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Bought by Polar Asset Management Partners Inc. - MarketBeat

Dec 05, 2024

Dec 04, 2024

235,498 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Patient Square Capital LP - MarketBeat

Dec 04, 2024

Erste Asset Management GmbH Makes New $2.05 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Dec 04, 2024

Dec 03, 2024

Keratoconus Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix - Barchart

Dec 03, 2024

Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts - Inkl

Dec 03, 2024

Ocular Therapeutix announces over 300 subjects randomized in SOL-1 - Yahoo Finance

Dec 03, 2024

Dec 02, 2024

Ocular Pokes Ahead on Randomized Subjects - Baystreet.ca

Dec 02, 2024

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1 - The Manila Times

Dec 02, 2024

Nov 30, 2024

Braidwell LP Has $19.49 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Nov 30, 2024

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is Knoll Capital Management LLC's 10th Largest Position - MarketBeat

Nov 30, 2024

Nov 29, 2024

OCUL (Ocular Therapeutix) 9-Day RSI : 56.85 (As of Nov. 29, 2024) - GuruFocus.com

Nov 29, 2024

Neuropathic Ocular Pain Market Is Booming Worldwide 2024-2031 | - openPR

Nov 29, 2024

Nov 28, 2024

Acuta Capital Partners LLC Cuts Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Nov 28, 2024

OCUL (Ocular Therapeutix) 9-Day RSI : 56.85 (As of Nov. 28, 2024) - GuruFocus.com

Nov 28, 2024

Learn to Evaluate (OCUL) using the Charts - Stock Traders Daily

Nov 28, 2024

Nov 27, 2024

Ocular Therapeutix chief scientific officer sells shares worth $26,561 By Investing.com - Investing.com Nigeria

Nov 27, 2024

Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock By Investing.com - Investing.com Canada

Nov 27, 2024

Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock - Investing.com India

Nov 27, 2024

Ocular Therapeutix chief development officer sells shares worth $26,101 By Investing.com - Investing.com Nigeria

Nov 27, 2024

Ocular Therapeutix chief development officer sells shares worth $26,101 - Investing.com

Nov 27, 2024

Ocular Therapeutix executive sells shares for $16,326 - Investing.com

Nov 27, 2024

Ocular Therapeutix executive sells shares for $16,326 By Investing.com - Investing.com Australia

Nov 27, 2024

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 27, 2024

Ocular Therapeutix chief scientific officer sells shares worth $26,561 - Investing.com

Nov 27, 2024

Nov 26, 2024

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences - GlobeNewswire

Nov 26, 2024

Ocular Therapeutix to Present Clinical Data at Major Healthcare Conferences in December - StockTitan

Nov 26, 2024

Nov 24, 2024

OCUL (Ocular Therapeutix) EBITDA per Share : $-1.15 (TTM As of Sep. 2024) - GuruFocus.com

Nov 24, 2024

Nov 23, 2024

Banco Santander S.A. Sells 205,137 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Nov 23, 2024

Nov 22, 2024

Ocular Therapeutix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Nov 16, 2024

GSA Capital Partners LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Nov 16, 2024

Nov 15, 2024

Ocular Therapeutix (NASDAQ:OCUL) Given New $15.00 Price Target at HC Wainwright - MarketBeat

Nov 15, 2024

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024